-
Stocks traded mostly higher during the Asian session. Nikkei gained 0.4%, Kospi added 0.3% and indices from China gained 0.3-0.5%. S&P/ASX 200 dropped 0.5%
-
DAX futures point to a flat opening of the European session
-
Total confirmed coronavirus case count in Germany exceeded 1 million
-
AstraZeneca may hold another coronavirus vaccine trial after data from the first one was questioned
-
Trump said that deliveries of coronavirus vaccine in the United States will begin next week and front-line workers, medical staff as well as seniors will be the first ones to receive it
-
Negotiators from UK and EU will resume in-person talks in London this weekend. In other Brexit news, Reuters reported that decision on access of UK banks and financial firms to the European market will not be made this year
-
Germany looks to issue almost €180 billion on new debt in 2021
-
China plans to impose anti-dumping duties on Australian wine
-
Chinese industrial profits for October came in at 28.2% YoY
-
Bitcoin trades steady near $17,000 following yesterday's plunge
-
Commodities trade in narrow ranges
-
AUD and NZD are top moving major currencies while USD and CHF lag the most
Lower number of new coronavirus cases was reported yesterday as the Thanksgiving holiday limited testing capability of the United States. Source: worldometers, XTB
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
